Sushchyk Sarah, Xi Zheng-Xiong, Wang Jia Bei
Department of Pharmaceutical Sciences, University of Maryland Baltimore, Baltimore, Maryland (S.S., J.B.W.); Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland (Z.-X.X.).
Department of Pharmaceutical Sciences, University of Maryland Baltimore, Baltimore, Maryland (S.S., J.B.W.); Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland (Z.-X.X.)
J Pharmacol Exp Ther. 2016 May;357(2):248-57. doi: 10.1124/jpet.115.229542. Epub 2016 Feb 22.
Relapse to drug use is often cited as the major obstacle in overcoming a drug addiction. Whereas relapse can occur for a myriad of reasons, it is well established that complex neuroadaptations that occur over the course of addiction are major factors. Cocaine, as a potent dopamine transporter blocker, specifically induces alterations in the dopaminergic as well as other monoaminergic neurotransmissions, which lead to cocaine abuse and dependence. Evidence also suggests that adaptations in the endogenous opioids play important roles in pathophysiology of cocaine addiction. Following this evidence, we investigated a combination medication, levo-tetrahydropalmatine (l-THP) and low dose naltrexone (LDN), targeting primarily dopaminergic and endogenous opioid systems as a cocaine-relapse-prevention treatment. In the present study Wistar rats were used to assess the effects ofl-THP and LDN on cocaine self-administration, drug-seeking behavior during cocaine reinstatement, spontaneous locomotion, and effects on the endogenous opioid system. We determined that the combination ofl-THP and LDN reduces drug-seeking behavior during reinstatement more potently thanl-THP alone. Additionally, the combination ofl-THP and LDN attenuates the sedative locomotor effect induced byl-THP. Furthermore, we revealed that treatment with the combination ofl-THP and LDN has an upregulatory effect on both plasmaβ-endorphin and hypothalamic POMC that was not observed inl-THP-treated groups. These results suggest that the combination ofl-THP and LDN has great potential as an effective and well-tolerated medication for cocaine relapse prevention.
药物复吸常被视为克服药物成瘾的主要障碍。尽管复吸可能由多种原因引起,但成瘾过程中发生的复杂神经适应性变化是主要因素,这一点已得到充分证实。可卡因作为一种强效多巴胺转运体阻滞剂,特别会诱发多巴胺能以及其他单胺能神经传递的改变,从而导致可卡因滥用和依赖。有证据还表明,内源性阿片类物质的适应性变化在可卡因成瘾的病理生理学中发挥着重要作用。基于这一证据,我们研究了一种联合用药,即左旋四氢巴马汀(l-THP)和低剂量纳曲酮(LDN),主要针对多巴胺能和内源性阿片系统,作为一种预防可卡因复吸的治疗方法。在本研究中,使用Wistar大鼠来评估l-THP和LDN对可卡因自我给药、可卡因复燃期间的觅药行为、自发运动以及对内源性阿片系统的影响。我们确定,l-THP和LDN联合使用比单独使用l-THP更有效地减少了复燃期间的觅药行为。此外,l-THP和LDN联合使用减弱了l-THP诱导的镇静运动效应。此外,我们发现,l-THP和LDN联合治疗对血浆β-内啡肽和下丘脑POMC均有上调作用,而在l-THP治疗组中未观察到这种作用。这些结果表明,l-THP和LDN联合使用作为一种有效且耐受性良好的预防可卡因复吸药物具有巨大潜力。